Biography

Dr. Srinivasa Raju Datla is currently working as Postdoctoral Fellow at Cardiology Division of Emory University, Atlanta, U.S.A since 2008. In 1999, he was appointed as Pharmacologist at the Dr. Reddy`s Research Foundation, Hyderabad, India. In 2003, he was appointed as Sr.Research Scientist at the Ranbaxy Research Laboratories, Delhi, India.

Dr. Srinivasa Raju Datla received his B.Pharmacy in 1995 at Gulbarga University, India. He got M.Pharmacy in Pharmacology in 1999 from Andhra University, India. Dr. Srinivasa Raju Datla obtained Ph.D. from Melbourne University, Australia in 2008 in Cardiovascular Pharmacology.

Dr. Srinivasa Raju Datla`s current research interests are Cardiovascular Pharmacology, Drug Discovery, NADPH Oxidase, Oxidative Stress, Pharmacology.

Area of Interest:

Medicine

100%

Drug Discovery

62%

NADPH Oxidase

90%

Oxidative Stress

75%

Pharmacology

55%

Research Publications in Numbers

Books
0

Chapters
0

Articles
12

Abstracts
0

Selected Publications

Sutliff, R.L., L.L. Hilenski, A.M. Amanso, I. Parastatidis and A.E. Dikalova et al., 2013. Polymerase delta interacting Protein 2 sustains vascular structure and function. Arterioscler Thromb. Vasc. Biol., 33: 2154-2161.
PubMed |
Datla, S.R. and K.K. Griendling, 2010. Reactive oxygen species, NADPH oxidases and hypertension. Hypertension, 56: 325-330.
Lee, M.Y., A.S. Martin, P.K. Mehta, A.E. Dikalova and A.M. Garrido et al., 2009. Mechanisms of vascular smooth muscle NADPH oxidase 1 (Nox1) contribution to injury-induced neointimal formation. Arterioscler Thromb. Vasc. Biol., 29: 480-487.
PubMed |
Chan, E.C., G.T. Jones, G.J. Dusting, S.R. Datla and F. Jiang, 2009. Prevention of aortic elastic lamina defects by losartan in apolipoprotein (E)-deficient mouse. Clinical Exp. Pharmacol. Physiol., 36: 919-924.
CrossRef | Direct Link |
Datla, S.R., H. Peshavariya, Y. Guo, G.J. Dusting and F. Jiang, 2007. Important role of Nox4 type NADPH oxidase in angiogenic responses in human microvascular endothelial cells in vitro. Arterioscler. Thromb. Vas. Biol., 27: 2319-2324.
CrossRef | Direct Link |
Datla, S.R., G.J. Dusting, T.A Mori, C.J. Taylor, K.D. Croft and F. Jiang, 2007. Induction of heme oxygenase-1 in vivo suppresses NADPH oxidase derived oxidative stress. Hypertension, 50: 636-642.
CrossRef | Direct Link |
Chan, E.C., S.R. Datla, R. Dilley, H. Hickey, G.R. Drummond and G.J. Dusting, 2007. Adventitial application of an NADPH oxidase inhibitor in vivo reduces neointima formation and endothelial dysfunction in rabbits. Cardiovascul. Res., 75: 710-718.
CrossRef | Direct Link |
Singh, S.K., S. Vobbalareddy, S.R. Kalleda, S.R. Casturi and S.R. Datla et al, 2006. Identification of 2-hydroxymethyl-4-[5-(4-methoxyphenyl)-3-trifluoromethyl-pyrazol-1-yl]-N-p ropionylbenzenesulfonamide sodium as a potential COX-2 inhibitor for oral and parenteral administration. Bioorg. Med. Chem., 14: 8626-8634.
Mamnoor, P.K., P. Hegde, S.R. Datla, R.K. Damarla, R. Rajagopalan and R. Chakrabarti, 2006. Antihypertensive effect of ragaglitazar: A novel PPAR α γ dual activator. Pharmacol. Res., 54: 129-135.
CrossRef |
Jiang, F., S.J. Roberts, S.R. Datla and G.J. Dusting, 2006. NO modulates NADPH oxidase function via heme oxygenase-1 in human endothelial cells. Hypertension, 48: 950-957.
CrossRef | Direct Link |
Chakrabarti, R., P. Misra, R.K. Vikramadithyan, M. Premkumar and J. Hiriyan et al., 2004. Antidiabetic and hypolipidemic potential of DRF 2519--a dual activator of PPAR-alpha and PPAR-gamma. Eur. J. Pharmacol., 491: 195-206.
PubMed |
Mamidi, R.N., R. Mullangi, J. Kota, R. Bhamidipati and A.A. Khan et al., 2002. Pharmacological and pharmacokinetic evaluation of celecoxib prodrugs in rats. Biopharm. Drug Dispos., 23: 273-282.
PubMed |